Otros idiomas Legend Biotech Corporation

Acciones

LEGN

US52490G1022

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 16/07/2026			Variación 5 días	Varia. 1 de enero.
22,71 ^USD	-1,43 %		-18,51 %	+4,46 %

16/07	Genscript anuncia ventas de Carvykti por 657 millones de USD bajo su acuerdo de licencia	MT
07/07	LEGEND BIOTECH CORPORATION : RBC Capital Markets mantiene su recomendación de compra	ZM

Otros idiomas

16/07	Genscript Associate Reports $657 Million in Carvykti Sales Under License Agreement
18/06	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Interim US-Iran Deal Lifts Risk Sentiment
18/06	Legend Biotech Prices $226 Million ADS Offering
18/06	Legend Biotech Corporation Announces Pricing of Public Offering
17/06	Legend Biotech ADSs Fall After Company Announces Public Offering
17/06	Stocks to Watch : Smith & Wesson, Logistic Properties of the Americas, Legend Biotech
17/06	Legend Biotech Starts $225 Million Public Offering
17/06	Legend Biotech Corporation Announces Proposed Public Offering
15/06	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
15/06	Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma
15/06	Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma
14/06	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
14/06	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501 in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
03/06	Genscript Associate to Present Data for Lymphoma Drug at European Conference; Shares Surge 11%
02/06	Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment
02/06	Legend Biotech Corporation Announces Late-Breaking Oral Presentation of Initial Phase 1 in Vivo Car-T Data with Lb2501 in Non-Hodgkin Lymphoma
02/06	Legend's experimental cell therapy shows promise in blood cancer patients
02/06	Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
01/06	Legend Points Carvykti Toward Use in Earlier Setting, RBC Says
01/06	Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
01/06	Legend Biotech Corporation Presents First-In-Human LB2102 Results And New CARVYKTI Data At ASCO 2026
21/05	Legend Biotech Announces Presentations at ASCO 2026
13/05	Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says
12/05	Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Legend Biotech : LEGN Q1 2026 Slide 5.6.2026